Persistent restoration to the immunosupportive tumor microenvironment in glioblastoma by bevacizumab-Reference-Cited by-同舟云学术

Persistent restoration to the immunosupportive tumor microenvironment in glioblastoma by bevacizumab

Published:2018-12-21 Issue:2 Volume:110 Page:499-508
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Tamura Ryota¹,Tanaka Toshihide²,Ohara Kentaro³,Miyake Keisuke⁴,Morimoto Yukina¹,Yamamoto Yohei²,Kanai Ryuichi⁵,Akasaki Yasuharu⁶,Murayama Yuichi⁶,Tamiya Takashi⁴,Yoshida Kazunari¹,Sasaki Hikaru¹^ORCID

Affiliation:

1. Department of NeurosurgeryKeio University School of Medicine Tokyo Japan

2. Department of NeurosurgeryJikei University Kashiwa Hospital Chiba Japan

3. Division of Diagnostic PathologyKeio University School of Medicine Tokyo Japan

4. Department of NeurosurgeryKagawa University Hospital Kagawa Japan

5. Department of NeurosurgeryEiju General Hospital Tokyo Japan

6. Department of NeurosurgeryJikei University Hospital Tokyo Japan

Funder

Ministry of Education, Culture, Sports, Science and Technology and the Japan Society for the Promotion of Science (KAKENHI)

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.13889

Reference44 articles.

1. Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma

2. A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma

3. Bevacizumab for malignant gliomas: current indications, mechanisms of action and resistance, and markers of response

4. Histopathological investigation of glioblastomas resected under bevacizumab treatment

5. “Paradoxical” findings of tumor vascularity and oxygenation in recurrent glioblastomas refractory to bevacizumab

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune checkpoint pathways in glioblastoma: a diverse and evolving landscape;Frontiers in Immunology;2024-09-13

2. Response to correspondence on an exploratory prospective phase II study of preoperative neoadjuvant bevacizumab and temozolomide for newly diagnosed glioblastoma;Journal of Neuro-Oncology;2024-08-31

3. Comparative analyses of immune cells and alpha-smooth muscle actin-positive cells under the immunological microenvironment between with and without dense fibrosis in primary central nervous system lymphoma;Brain Tumor Pathology;2024-08-26

4. Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial;Journal of Clinical Oncology;2024-04-01

5. Status of alternative angiogenic pathways in glioblastoma resected under and after bevacizumab treatment;Brain Tumor Pathology;2024-04